Home LiteratureArticle Details
PMID: 20498257 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice.

Infection and immunity ·Vol. 78 ·No. 8 ·2010-08-00 ·Pages 3432-42

Wieser A, Romann E, Magistro G, Hoffmann C, Nörenberg D, Weinert K, Schubert S

Abstract

Infections due to extraintestinal pathogenic Escherichia coli (ExPEC) are common in humans and animals and include urinary tract infections (from uropathogenic E. coli [UPEC]), septicemia, and wound infections. These infections result in significant morbidity and mortality and in high health care costs. In view of the increasing number of ExPEC infections and the ever-growing antibiotic resistance capability of ExPEC isolates, preventive measures such as an effective vaccine against ExPEC are desirable. An ExPEC vaccine may be cost-effective for select patient groups. Previous vaccine candidates consisted of single target proteins or whole ExPEC cells. Here we describe a subunit vaccine against ExPEC which is based on immunodominant epitopes of the virulence-associated ExPEC proteins FyuA, IroN, ChuA, IreA, Iha, and Usp. Using a novel approach of computer-aided design, two completely artificial genes were created, both encoding eight peptide domains derived from these ExPEC proteins. The recombinant expression of these two genes resulted in a protein vaccine directed against ExPEC but not against commensal E. coli of the gut flora. In mice, the vaccine was highly immunogenic, eliciting both strong humoral and cellular immune responses. Nasal application resulted in high secretory immunoglobulin A (sIgA) production, which was detectable on the mucosal surface of the urogenital tract. Finally, it conveyed protection, as shown by a significant reduction of bacterial load in a mouse model of ExPEC peritonitis. This study provides evidence that a novel vaccine design encompassing distinct epitopes of virulence-associated ExPEC proteins may represent a means for providing a protective and pathogen-specific vaccine.

MeSH Terms
Administration, Intranasal Animals Antibodies, Bacterial/blood Epitopes/genetics,immunology Escherichia coli Infections/immunology,prevention & control Escherichia coli Proteins/administration & dosage,genetics,immunology Escherichia coli Vaccines/administration & dosage,genetics,immunology Female Immunity, Mucosal Immunoglobulin A, Secretory/analysis,immunology Lymphocytes/immunology Mice Mice, Inbred BALB C Peritonitis/immunology,prevention & control Vaccines, Subunit/administration & dosage,genetics,immunology Vaccines, Synthetic/administration & dosage,genetics,immunology
Chemicals
Antibodies, Bacterial Epitopes Escherichia coli Proteins Escherichia coli Vaccines Immunoglobulin A, Secretory Vaccines, Subunit Vaccines, Synthetic
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Wieser Andreas
Max von Pettenkofer Institut für Hygiene und Medizinische Mikrobiologie, Marchioninistr. 17, 81377 Munich, Germany.
Romann Eva
Magistro Giuseppe
Hoffmann Christiane
Nörenberg Dominik
Weinert Kirsten
Schubert Sören
References (49)
49 references, click to expand
  1. Crystal structure of the outer membrane active transporter FepA from Escherichia coli.
    Nat Struct Biol. 1999 Jan;6(1):56-63 PMID: 9886293
  2. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells.
    Urology. 2002 Sep;60(3):521-6 PMID: 12350510
  3. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
    Crit Care Med. 2001 Jul;29(7):1303-10 PMID: 11445675
  4. The Vienna RNA websuite.
    Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W70-4 PMID: 18424795
  5. Extraintestinal pathogenic Escherichia coli: "the other bad E coli".
    J Lab Clin Med. 2002 Mar;139(3):155-62 PMID: 11944026
  6. Aspects of genome plasticity in pathogenic Escherichia coli.
    Int J Med Microbiol. 2007 Nov;297(7-8):625-39 PMID: 17462951
  7. Enhancement of the Listeria monocytogenes p60-specific CD4 and CD8 T cell memory by nonpathogenic Listeria innocua.
    J Immunol. 1999 Apr 15;162(8):4781-9 PMID: 10202020
  8. Antigen-specific responses accelerate bacterial clearance in the bladder.
    J Immunol. 2006 Mar 1;176(5):3080-6 PMID: 16493067
  9. Transcriptome of uropathogenic Escherichia coli during urinary tract infection.
    Infect Immun. 2004 Nov;72(11):6373-81 PMID: 15501767
  10. Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations.
    Microbiology (Reading). 2001 Jun;147(Pt 6):1671-1676 PMID: 11390698
  11. Unconventional immunology and urinary tract infection.
    J Urol. 1999 Jan;161(1):3 PMID: 10037354
  12. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.
    Infect Immun. 1991 Mar;59(3):1153-61 PMID: 1671776
  13. Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development.
    Expert Rev Vaccines. 2006 Feb;5(1):45-54 PMID: 16451107
  14. Prediction of MHC class I binding peptides using profile motifs.
    Hum Immunol. 2002 Sep;63(9):701-9 PMID: 12175724
  15. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection.
    Infect Immun. 2007 Aug;75(8):3941-9 PMID: 17517861
  16. Bacterial iron transport related to virulence.
    Contrib Microbiol. 2005;12:210-233 PMID: 15496782
  17. Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV--study in domestic pigs.
    Vaccine. 2009 Dec 11;28(2):293-8 PMID: 19879232
  18. Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains.
    Infect Immun. 1990 May;58(5):1281-9 PMID: 2182540
  19. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
    J Infect Dis. 2000 Feb;181(2):774-8 PMID: 10669375
  20. Iron transport in Escherichia coli. Crystal structure of FhuA, an outer membrane iron and antibiotic transporter.
    Adv Exp Med Biol. 2000;485:33-43 PMID: 11109084
  21. Mucosal immunity and vaccines.
    Nat Med. 2005 Apr;11(4 Suppl):S45-53 PMID: 15812489
  22. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis.
    J Infect Dis. 2005 Jan 1;191(1):46-50 PMID: 15593002
  23. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
    Eur J Clin Microbiol Infect Dis. 2001 Sep;20(9):617-25 PMID: 11714042
  24. Genes of the major histocompatibility complex of the mouse.
    Annu Rev Immunol. 1983;1:529-68 PMID: 6152713
  25. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant.
    J Oral Sci. 2003 Mar;45(1):25-31 PMID: 12816361
  26. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection.
    J Immunol. 1997 Apr 1;158(7):3366-71 PMID: 9120295
  27. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women.
    Int J Antimicrob Agents. 1999 May;11(3-4):305-8 PMID: 10394988
  28. Deaths: injuries, 2002.
    Natl Vital Stat Rep. 2006 Jan 31;54(10):1-124 PMID: 16485447
  29. Distinctive homing profile of pathogen-specific activated lymphocytes in human urinary tract infection.
    Clin Immunol. 2008 Sep;128(3):427-34 PMID: 18585960
  30. Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein.
    Microb Pathog. 2000 Mar;28(3):183-9 PMID: 10702359
  31. Analysis of genome plasticity in pathogenic and commensal Escherichia coli isolates by use of DNA arrays.
    J Bacteriol. 2003 Mar;185(6):1831-40 PMID: 12618447
  32. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.
    Vaccine. 2007 May 10;25(19):3859-70 PMID: 17306426
  33. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains.
    Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12879-84 PMID: 16912116
  34. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem.
    Microbes Infect. 2003 Apr;5(5):449-56 PMID: 12738001
  35. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection.
    J Urol. 1999 Jan;161(1):338-41 PMID: 10037434
  36. A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge.
    Vaccine. 2009 Aug 27;27(39):5313-9 PMID: 19615961
  37. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled.
    J Biol Chem. 2007 Jul 20;282(29):21259-67 PMID: 17504765
  38. Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections.
    J Infect Dis. 2002 Sep 15;186(6):859-64 PMID: 12198625
  39. Mucosal immunization with iron receptor antigens protects against urinary tract infection.
    PLoS Pathog. 2009 Sep;5(9):e1000586 PMID: 19806177
  40. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
    Ann Intern Med. 2001 Jul 3;135(1):41-50 PMID: 11434731
  41. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.
    Tissue Antigens. 2002 Jun;59(6):443-51 PMID: 12445314
  42. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues.
    Nat Immunol. 2002 Dec;3(12):1177-84 PMID: 12436110
  43. Addressing the challenge of extended-spectrum beta-lactamases.
    Curr Opin Investig Drugs. 2009 Feb;10(2):172-80 PMID: 19197795
  44. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC.
    J Infect Dis. 2000 May;181(5):1753-4 PMID: 10823778
  45. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997.
    J Infect Dis. 2001 Feb 15;183(4):596-603 PMID: 11170985
  46. Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.
    Microbiol Immunol. 2003;47(10):797-802 PMID: 14605446
  47. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli.
    Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17020-4 PMID: 12471157
  48. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli.
    Infect Immun. 2007 Apr;75(4):1916-25 PMID: 17145948
  49. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.
    Infect Immun. 2003 Dec;71(12):7164-9 PMID: 14638809
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
1098-5522
Published
2010-08-00
Epub
2010-00-24
Pages
3432-42
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC2916271
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com